Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, with Optional Open-Label Extension

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, with Optional Open-Label Extension

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ASCEND; ASCEND in SPMS
  • Sponsors Biogen

Most Recent Events

  • 12 Apr 2025 Results assessing cognitive change in secondary progressive multiple sclerosis from ASCEND cognition substudy were published in the Journal of Neurology.
  • 01 Dec 2022 Results assessing the sensitivity and clinical meaningfulness of ODRS using natalizumab Phase 3 data sets -AFFIRM in relapsing-remitting MS and ASCEND in secondary progressive MS, published in the Multiple Sclerosis Journal
  • 09 Nov 2022 Results (from studies EXPAND and ASCEND) assessing Cost Effectiveness of Siponimod for Secondary Progressive Multiple Sclerosis in Turkey presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top